LifeCycle Pharma A/S to Host Conference Call Announcing Interim Results for the Third Quarter of 2008

Investor Service Announcement no.7/2008
To: NASDAQ OMX Copenhagen	Hørsholm,  Denmark,   November 20, 2008

LifeCycle Pharma A/S to Host Conference Call Announcing 
Interim Results for the Third Quarter of 2008 
LifeCycle Pharma A/S (OMX: LCP) will announce interim results for the third
quarter of 2008 (January 1 - September 30) on Thursday, November 27, 2008. The
results will be announced before the opening of Nasdaq OMX Nordic Exchange
Copenhagen. LCP's Executive Management will host an accompanying conference
call to discuss the financial results on Thursday, November 27, 2008, at 15:00
CET (Denmark); 14:00 GMT (London); 09:00 AM ET (New York); 06:00 AM PT (San
Francisco). 

To access the live conference call, please dial one of the following numbers: 
+1 866 966 5335 (US) 
+44 2030 032 666 (UK) 
+45 8088 8649 (DK) 

An audio replay of the conference call will be available on www.lcpharma.com
from Friday, November 28, 2008, at 16:00 CET (Denmark); 15:00 GMT (London);
10:00 AM ET (New York); 07:00 AM PT (San Francisco), through Friday, December
26, 2008, by dialing +44 2081 961 998 (UK) or +1 866 583 1035 (US), and
entering access code 8403 264#. 

For more information, please contact: 
Dr. Jim New 
President & CEO
Phone: +45 7033 3300
JSN@lcpharma.com

About LifeCycle Pharma A/S (“LCP”): LCP is an emerging specialty pharmaceutical
company that, through innovative technologies, is able to rapidly develop a
portfolio of differentiated products to meet the unique needs of key
therapeutic markets and patient populations. This includes products for
immunosuppression, specifically organ transplantation, and to combat certain
cardiovascular diseases. By using its unique and patented delivery technology,
MeltDose®, LCP is able to develop drugs with enhanced absorption and thereby
increased bioavailability. LCP has a cholesterol lowering product, FenoglideTM,
currently on the US market and a diversified near‐ and medium‐term pipeline,
including four product candidates in clinical trials and two in preclinical
stages of development. LCP is listed on the OMX Nordic Exchange Copenhagen
under the trading symbol (OMX: LCP). For further information, please visit
www.lcpharma.com